Literature DB >> 9949199

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.

G Schilling1, M W Becher, A H Sharp, H A Jinnah, K Duan, J A Kotzuk, H H Slunt, T Ratovitski, J K Cooper, N A Jenkins, N G Copeland, D L Price, C A Ross, D R Borchelt.   

Abstract

Huntington's disease (HD) is an inherited, neurodegenerative disorder caused by the expansion of a glutamine repeat in the N-terminus of the huntingtin protein. To gain insight into the pathogenesis of HD, we generated transgenic mice that express a cDNA encoding an N-terminal fragment (171 amino acids) of huntingtin with 82, 44 or 18 glutamines. Mice expressing relatively low steady-state levels of N171 huntingtin with 82 glutamine repeats (N171-82Q) develop behavioral abnormalities, including loss of coordination, tremors, hypokinesis and abnormal gait, before dying prematurely. In mice exhibiting these abnormalities, diffuse nuclear labeling, intranuclear inclusions and neuritic aggregates, all immunoreactive with an antibody to the N-terminus (amino acids 1-17) of huntingtin (AP194), were found in multiple populations of neurons. None of these behavioral or pathological phenotypes were seen in mice expressing N171-18Q. These findings are consistent with the idea that N-terminal fragments of huntingtin with a repeat expansion are toxic to neurons, and that N-terminal fragments are prone to form both intranuclear inclusions and neuritic aggregates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9949199     DOI: 10.1093/hmg/8.3.397

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  274 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

2.  Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease.

Authors:  Eunice Y Yuen; Jing Wei; Ping Zhong; Zhen Yan
Journal:  Neurobiol Dis       Date:  2012-02-28       Impact factor: 5.996

3.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

Review 4.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 5.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

7.  PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.

Authors:  Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada
Journal:  Sci Transl Med       Date:  2017-12-06       Impact factor: 17.956

8.  Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.

Authors:  D Hutchinson; V Ho; M Dodd; H N Dawson; A C Zumwalt; D Schmitt; C A Colton
Journal:  Neuroscience       Date:  2007-07-21       Impact factor: 3.590

Review 9.  Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

Authors:  Joanna L Jankowsky; Alena Savonenko; Gabriele Schilling; Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 10.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.